CER Policy Does Not Equate To Head-To-Head Trials, UBC's Luce Says
This article was originally published in The Gray Sheet
Executive Summary
While there are many fears that comparative effectiveness research will be used to pick winners and losers when products are pitted against one another, United BioSource Corp.'s Bryan Luce does not see head-to-head trials becoming the primary focus of CER activity in the U.S., at least on a federal level
You may also be interested in...
Institute Of Medicine Sets Top 100 Comparative Effectiveness Priorities
A June 30 Institute of Medicine 1report to Congress includes dozens of surgical- and device-related topics among a list of 100 recommended priorities for federally-funded comparative effectiveness research
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.